CAH 2025 | Professor Lei Fan: Advancing a Paradigm Shift in the Treatment of Indolent Lymphoma and Exploring a China-Specific Model for Lifelong Disease Management

CAH 2025 | Professor Lei Fan: Advancing a Paradigm Shift in the Treatment of Indolent Lymphoma and Exploring a China-Specific Model for Lifelong Disease Management

2025.07.16
In early summer, the historic city of Xi’an welcomed a gathering of leading experts at the 19th Annual Meeting of the Chinese Association of Hematologists and the 2025 China Annual Hematology Conference (CAH 2025), held from June 20 to 22. The event was co-hosted by the Chinese Medical Doctor Association and its Hematology Branch, in collaboration with the National Clinical Research Center for Hematologic Diseases – Peking University Institute of Hematology, and the First Affiliated Hospital of Xi’an Jiaotong University.
Prof. Yao Zhu: A “Prevention-Treatment-Research” Integrated Approach to Prostate Cancer Management | 2025 Pujiang Prostate Cancer Conference

Prof. Yao Zhu: A “Prevention-Treatment-Research” Integrated Approach to Prostate Cancer Management | 2025 Pujiang Prostate Cancer Conference

2025.07.14
The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology (CACA-GO) Prostate Cancer Conference, and the Chinese Prostate Cancer Consortium (CPCC) Annual Meeting. Themed “Global Wisdom · Chinese Practice · Precise Breakthroughs,” the event brought together domestic and international experts to exchange the latest advances and practical experience in prostate cancer.
Professor Xudong Yao: The “Shanghai Tenth Hospital Experience” in Prostate Cancer Diagnosis, Treatment, and Research2025 Pujiang Prostate Cancer Conference

Professor Xudong Yao: The “Shanghai Tenth Hospital Experience” in Prostate Cancer Diagnosis, Treatment, and Research2025 Pujiang Prostate Cancer Conference

2025.07.14
The “2025 Pujiang Prostate Cancer Academic Conference,” held in Shanghai from June 27 to 28, was jointly hosted alongside the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Subcommittee of the Chinese Anti-Cancer Association (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC). With the theme “Global Wisdom, Chinese Practice, and Precision Breakthroughs,” the event gathered leading domestic and international experts to share the latest advances and clinical insights in prostate cancer care. At the conference, Professor Xudong Yao, Director of the Department of Urology at Shanghai Tenth People’s Hospital (Tongji University Affiliated Tenth People’s Hospital), delivered a keynote presentation titled “Exploration and Outlook on the Comprehensive Management of Prostate Cancer.” In an interview with Oncology Frontier – UroStream, he discussed his team’s experience and scientific work in prostate cancer management.
Professor Jianming Guo Shares Zhongshan’s Approach to Postoperative Management of Prostate Cancer Complications2025 Pujiang Prostate Cancer Academic Conference

Professor Jianming Guo Shares Zhongshan’s Approach to Postoperative Management of Prostate Cancer Complications2025 Pujiang Prostate Cancer Academic Conference

2025.07.14
The 2025 Pujiang Prostate Cancer Academic Conference—jointly held with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC)—took place in Shanghai on June 27–28. At the conference, Professor Jianming Guo from Zhongshan Hospital, Fudan University, delivered a keynote presentation on “Managing Postoperative Complications After Prostate Cancer Surgery” and later shared additional insights in an interview with Oncology Frontier – UroStream, highlighting Zhongshan’s experience in perioperative enhanced recovery after surgery (ERAS) for prostate cancer patients.
ASCO China Focus | “Rebirth: I Want to Keep My Bladder”—Professor Yijun Shen Presents Phase II ReBirth Study on Stratified Bladder-Sparing Approaches After Neoadjuvant Immunochemotherapy

ASCO China Focus | “Rebirth: I Want to Keep My Bladder”—Professor Yijun Shen Presents Phase II ReBirth Study on Stratified Bladder-Sparing Approaches After Neoadjuvant Immunochemotherapy

2025.07.10
To live or to live well?” This Shakespearean dilemma continues to haunt many patients with bladder cancer. How to provide longer-lasting disease control while preserving the bladder through safer and more tolerable strategies has become a central challenge in urologic oncology. At the 2025 ASCO Annual Meeting, Professor Yijun Shen from Fudan University Shanghai Cancer Center presented the Phase II ReBirth study, which evaluates stratified bladder-sparing treatment strategies based on whether patients achieve clinical complete response (cCR) following neoadjuvant immunochemotherapy.